with pharmacist-managed ESA clinics (nϭ314) and at six sites with usual care only (nϭ167); outpatients were followed for 6 months in 2009. We took a VA perspective with projections over a five-year time horizon; costs and effectiveness values were discounted at 3%/yr. Strategy-specific likelihoods of target range hemoglobin values (10-12 g/dl) were based on study results. Utilities for ND-CKD and ESA-related adverse events and their likelihood were obtained from the literature. ESA costs were based on average monthly epoetin and darbepoetin doses per patient during the study and VA ESA cost data. RESULTS: In the base case analysis, cost and effectiveness were $12,500 and 2.096 quality-adjusted life-years (QALYs) in the pharmacistmanaged ESA clinics and $15,500 and 2.093 QALYs in usual care; ESA clinics dominated usual care. In one-way sensitivity analyses, ESA clinics no longer dominated if their patients' probability of being in the target range fell to 0.54 (base case 0.71) or if the mean cost/month of epoetin or darbepoetin in ESA clinics increased to approximately $360 (base case $211) or $460 (base case $250), respectively. When all parameters were varied simultaneously in a probabilistic sensitivity analysis, ESA clinics were favored Ն80% of the time regardless of willingness-to-pay threshold. CONCLUSIONS: Pharmacist-managed ESA clinics were less costly and more effective than usual care in patients receiving ESAs for anemia and ND-CKD. Results were robust to variation and support the use of pharmacist-managed ESA clinics.
OBJECTIVES: Immunosuppressive agents have affected the incidence of acute rejection and early graft survival. The purpose of this study was to evaluate the cost-utility of sirolimus versus tacrolimus for primary prevention of graft rejection in renal transplant recipients using the Mexican Institute of Social Security (IMSS) perspective. METHODS: A Markov model was developed to estimate the cost-effectiveness of sirolimus versus tacrolimus to prevent graft rejection in adult patients with end-stage renal disease (ESRD). The model estimates total costs and QALYs per patient in each prophylaxis group. To extrapolate trial results to lifetime horizon, the model was extended through one-year Markov cycles. The probabilities of experiencing a graft loss, dialysis, and death were estimated from trial published data; long-term mortality, acquisition costs, and direct treatment costs were retrieved using IMSS published sources. Cost utility assessment was expressed in terms of cost per QALY gained. All costs are presented in 2011 US dollars. Probabilistic sensitivity analyses were carried out to test the robustness of the results. RESULTS: In comparison to tracolimus, sirolimus improved life expectancy, number of QALYs gained, and reduced incidence of complications. The lifetime overall costs of prevent graft rejection in adult patients with ESRD resulted in a cost per QALY gained of Ͻ$5846. Over the lifetime period, sirolimus was estimated to gain 8.18 QALYs per patient compared to 7.33 QALYs for tacrolimus. Sirolimus is estimated to be cost-saving compared to tacrolimus. Notably, results suggest that sirolimus has a 78% probability of being dominant over tacrolimus strategy, with 100% of probability in showing an incremental cost-effectiveness ratio at or below US$13,000 (1 GDP per capita in Mexico) per QALY gained. CONCLUSIONS: This analysis suggests that at IMSS, sirolimus in comparison to tacrolimus for prevention of graft rejection in adults patient with ESRD is likely to be cost saving alternative.
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COST-EFFECTIVENESS ANALYSIS OF SOLIFENACIN SUCCINATE VERSUS TROSPIUM CHLORIDE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN GERMANY
Hart WM 1 , Nazir J 2 1 EcoStat Consulting Ltd, London, UK, 2 Astellas Pharma Europe Ltd., Staines, UK OBJECTIVES: To carry out a cost-utility analysis comparing initial treatment of patients with overactive bladder (OAB) with solifenacin 5 mg/day versus either trospium 20mg twice a day or trospium 60 mg/day from the perspective of the German National Health Service. METHODS: A decision analytic model with a three-month cycle was developed to follow a cohort of OAB patients treated with either solifenacin or trospium during a one-year period. Costs and utilities were accumulated as patients transitioned through the four cycles in the model. Some of the solifenacin patients were titrated from 5mg to 10mg/day at 3 months. Utility values were obtained from the published literature and pad use was based on a US resource utilisation study. Adherence rates for individual treatments were derived from a UK GP database review. The change in the mean number of urgency urinary incontinence episodes/day from after 12 weeks was the main outcome measure. Baseline effectiveness values for solifenacin and trospium were calculated using the Poisson distribution. Patients who failed second-line therapy were referred for a specialist visit. Results were expressed in terms of incremental cost-utility ratios. RESULTS: Total annual costs for solifenacin, trospium 20mg and trospium 60mg were 982.28 €, 863.23 € and 880.37 € respectively. Drug use represented 47%, 32% and 33% of total costs and pad use varied between 42% and 55%. Differences between cumulative utilities were small but favoured solifenacin (0.6887 vs. 0.6828 to 0.6830). The baseline incremental cost-effectiveness ratio ranged from 17,104 € to 20,533 per QALY. CONCLUSIONS: Solifenacin would appear to be cost-effective with an incremental cost-utility of no more than 21,000 €/QALY. Small differences in utility between the alternatives, however, means that the results are sensitive to adjustments in the values of the assigned utilities, effectiveness and discontinuation rates.
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PUK22 COMPARISON OF UTILITY SCORE AND QUALITY OF LIFE SCORE IN THAI PATIENT BETWEEN TWICE AND THRICE-WEEKLY HEMODIALYSIS
Thaweethamcharoen T, Vasuvattakul S, Noparatayaporn P Mahidol University, Bangkok, Thailand OBJECTIVES: To compare the utility scores and quality of life scores between patients who have twice and thrice-weekly hemodialysis. METHODS: This was a cross-sectional analytical study in 5 hemodialysis sites of Nephrology Unit at Siriraj Hospital (the largest university hospital in Thailand), Face-to-face interview using EuroQol questionnaire (EQ-5D), VAS, and KDQOL-36 (consists of 3 kidney disease subscales and SF-12) was conducted between April 2011 and June 2011, one hundred and fifty-three hemodialysis patients were recruited from the chronic hemodialysis clinic unit. This study compared the difference of hemodialysis times in weekly to utility scores and quality of life scores of patients by using Independent Student's t-test. RESULTS: SF-6D (derived from SF12), EQ-5D (UK and Thai preference weight), and VAS between the patients who received twice and thrice-weekly hemodialysis were not significantly different (pϾ0.05). This is true as well for Symptom/ problem list, Effects of kidney disease, and burden of Kidney Disease scores. For SF-12, all of physical and mental domains were not significantly different as well as all of utility and kidney disease specific scores were not significantly associated with hemodialysis times in weekly intervals (all, pϽ0.05). CONCLUSIONS: These findings implied that thrice-weekly could not reflect the better quality of life than twice-weekly hemodialysis. There was no significant difference quality of life from the Symptom/ problem list, Effects of kidney disease, and burden of Kidney Disease between twice and thrice-weekly hemodialysis as well as the utility scores from SF-6D, EQ-5D and VAS. Further large cohort study of utility scores or cost effectiveness analysis between the difference of dialysis frequency at weekly intervals, however, should be conducted. OBJECTIVES: Analysis of EQ-5D data often focuses on changes in utility, ignoring valuable information from other parts of the instrument. Our objective was to explore how the utility index, EQ-5D profile, and EQ-VAS captured change in clinical trials of Mirabegron, a new treatment for overactive bladder (OAB). METHODS: Data were pooled from three phase III clinical trials that investigated the efficacy and safety of mirabegron versus placebo. Tolterodine ER 4mg was included as an active control in one study: 1) Europe and Australia (placebo, mirabegron 50mg and 100mg, and tolterodine 4mg ER); 2) USA and Canada (Placebo, Mirabegron 50mg and 100mg); and 3) USA, Canada and Europe (Placebo, and Mirabegron 25mg and 50mg. Data were collected at baseline, week 4, 8 and 12. Analyses were performed on full analysis and per protocol data sets using UK utilities. Analysis controlled for relevant patient characteristics. Analysis of Covariance identified changes from baseline at each time point in utilities and EQ-VAS, while Areas Under the Curve (AUC) were estimated to summarise intertemporal differences in effect. RESULTS: In per protocol analyses, mirabegron 50mg was superior to tolterodine 4mg in changes from baseline utilities after 12 weeks (pϽ0.05); similarly, AUC results showed mirabegron 50mg to be superior to tolterodine (pϽ0.05) and to placebo (pϽ0.05). In both cases, the benefit is already apparent at 4 weeks (pϽ0.05). EQ-VAS more consistently indicated superior outcomes: all three mirabegron doses showed statistically significant greater effectiveness compared to tolterodine at 12 weeks. Individual EQ-5D dimensions and the overall profile showed no significant differences between study arms. CONCLUSIONS: Despite slight contrasts in results between the EQ-5D derived utilities and EQ-VAS, mirabegron showed quicker and superior improvement in HR-QoL compared to tolterodine 4mg ER. Research is required to address future utility measurements, especially in relation to EQ-5D dimensions in OAB patients. OBJECTIVES: Examine role of caregiver in supporting treatment decisions towards blood transfusions among individuals with chronic kidney disease (CKD) currently not on dialysis. METHODS: An online survey was conducted in 1Q2011. All respondents were Ն18 years and diagnosed with Cancer by a physician. Participants were asked about blood transfusion history, presence of anemia, types and roles of caregivers in assisting with management of their CKD and making health and treatment decisions towards blood transfusion. RESULTS: Of 416 participants, 59% (nϭ246) were female; 40% (nϭ165) were Ͼ65 years. 35% (nϭ144) had stage 4 and 58% (nϭ240) stage 3 CKD. 54% (nϭ226) were anemic. 43% (nϭ179) had received blood transfusion, whereas, 57% (nϭ237) had no transfusions. 53% (nϭ220) reported that no one helped with their daily activities, 36% (nϭ150) said their spouse helped them, followed by child (9%, nϭ37), friend (7%, nϭ29), another relative (5%, nϭ21), parent (3%, nϭ12), paid helper (3%, nϭ12), visiting doctor/nurse (3%, nϭ12). Among those who sought caregiver help on daily basis (nϭ195), two-thirds (64%) reported being cared for by spouse, 42% said a friend, and 21% their child. When asked, who helped (always/sometimes) in making health and medical care decision, 86% said spouse, 51 % friend, and 46% child. Almost two-thirds (63%) indicated they had right amount of caregiver support in making treatment choice for blood transfusion, 61% reported they made an informed decision, whereas, 40% said they felt pressured by others. Higher percentage (74%) of previously transfused individuals agreed they have right amount of caregiver support in making a transfusion choice compared to not transfused group (55%). CONCLUSIONS: Caregivers play an important role in helping individuals with their health and medical treatment decisions. On a daily basis, primary caregivers are spouse, child, and friend. Individuals have right amount of caregiver support when making treatment decisions. 
PUK23 UNDERSTANDING THE EFFECTS ON HR-QOL OF TREATMENT FOR OVERACTIVE BLADDER: A DETAILED ANALYSIS OF EQ-5D CLINICAL TRIAL DATA FOR MIRABEGRON
PUK24 EXAMINING THE ROLE OF CAREGIVER TOWARDS BLOOD TRANSFUSION DECISIONS AMONG INDIVIDUALS WITH CHRONIC KIDNEY DISEASE
PUK25
ROLE OF HEALTH LITERACY ON KIDNEY TRANSPLANT PATIENTS IMMUNOSUPPRESSANT DRUGS INFORMATION NEEDS
OBJECTIVES:
Post-transplant expectations can be overwhelming. We assessed the relationship between health literacy and unmet immunosuppressant (IS) drug information needs in kidney transplant recipients. We hypothesized that patients with low health literacy have greater unmet IS drug information needs compared to patients with optimal health literacy. METHODS: A cross-sectional survey was mailed out to 300 kidney transplant patients recruited from a single urban transplant center. Inclusion criteria were receiving post-transplant care at the center and receiving the transplant 1 to 36 months before inception of the survey. A validated scale measured functional, communicative and critical health literacy. An unmet IS drug information need was defined as a person reporting some to a significant problem and too little information on areas related to IS drug management. A person with 7 or more unmet IS drug information needs was categorized as having high unmet IS drug information needs. Logistic regression was used to produce unadjusted and adjusted OR controlling for age, race, gender, and time since transplant. RESULTS: A response rate of 50% was obtained. 61.3% of respondents were male and the mean age was 56.7 (ϩ/Ϫ 11.2) years. Cronbach's alphas for functional, communicative, and critical health literacy respectively were 0.87, 0.88 and 0.83. Patients with high functional health literacy (ORunadjusted: 0.23 [0.07, 0.82]; ORadjusted: 0.26 [0.06, 1.09]) and patients using the transplant staff as a source of information about transplant medications (ORunadjusted: 0.43 [0.19, 0.94]; ORadjusted: 0.28 [0.10, 0.78]) were less likely to report high unmet IS drug information needs. CONCLUSIONS: Patients with low functional health literacy have high unmet IS drug information needs, which might affect the management of their condition. It is important to assess patients' health literacy, tailor communication and materials accordingly, and regularly reinforce IS issues in order to meet their IS drug information needs.
PUK26 EXAMINING KNOWLEDGE AND INFORMATION SEEKING BEHAVIORS TOWARDS BLOOD TRANSFUSION AMONG INDIVIDUALS WITH CHRONIC KIDNEY DISEASE
Naim A 1 , Gollins JR 2 , Reynolds C 3 , Walls D 4 1 Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2 Delta Modelling Group, Mount Prospect, IL, USA, 3 Benfield Group, Saint Louis, MO, USA, 4 BDJ Solutions, Medford, MA, USA OBJECTIVES: Examine knowledge and information seeking behaviors towards blood transfusions among individuals with Chronic Kidney Disease (CKD) currently not on dialysis. METHODS: An online survey was conducted from a nationally representative patient panel in 1Q2011. Respondents were Ն18 years and diagnosed with CKD by a physician. Participants were asked about blood transfusion history, information seeking behaviors, and knowledge about blood transfusion. RESULTS: Of 416 respondents, 59% (nϭ246) were female; 40% (nϭ165) were Ͼ65 years. 35% (nϭ144) had stage 4 and 58% (nϭ240) stage 3 CKD. 54% (nϭ226) were anemic. 43% (nϭ179) had received blood transfusion, whereas, 57% (nϭ237) had no transfusions. Top two sources of information were doctor (93.8%) and Internet (80.5%). Among those previously transfused, 62% received right amount of information, whereas, 34.6% received too little information, and 3.4% reported receiving too much information. More than 80% of transfused indicated they knew the reasons for and benefits of getting a blood transfusion. Less than two-thirds received information about effects, risks, and time it would take, and only 26% knew the costs. Over 60% said that it is extremely important to know right blood type, screening techniques and quality of blood, and risks of infections. Among previously transfused, only half (50%) agreed that they made an informed choice about receiving blood transfusions. Among the previously transfused, 77% agree that they knew the benefits compared with 49% not transfused. Similarly among previously transfused, 69% agreed that they knew the risks of blood transfusion compared to 51% with no transfusion history. CONCLUSIONS: Doctor's office and Internet are primary sources of information about blood transfusions. Gaps in knowledge exist about benefits, risks, and costs of blood transfusions. A significant number feel that they need more information about blood transfusion to make an informed choice. Providers should consider adopting shared-decision making with their patients.
PUK27 VALIDITY AND RELIABILITY OF KDQOL-36 IN THAI KIDNEY DISEASE PATIENT
Thaweethamcharoen T, Vasuvattakul S, Noparatayaporn P, Srimonkol W, Jariyayothin P, Sukthinthai N, Aiyasanon N, Kitisriworapan P, Jantarakana K Mahidol University, Bangkok, Thailand OBJECTIVES: To evaluate the reliability and validity of the Thai translation of the KDQOL-36 questionnaire, by focus on kidney disease specific dimensions. The KDQOL-36 consists of SF-12, and 3 dimensions of kidney disease questionnaires (the Symptom/ Problem list, Effects of Kidney Disease on Daily Life, and Burden of Kidney disease). METHODS: Subjects were 167 hemodialysis patients and 62 peritoneal dialysis patients. Reliability was evaluated by using intraclass correlation coefficients (ICCs) for test-retest reliability assessment with face to face interview and Cronbach's alpha for internal consistency. Construct validity was supported with convergent and discriminant validity using correlation between SF-36, EQ-5D, VAS parameter and 3 dimensions of kidney disease questionnaires. Statistical analysis included descriptive statistics, Mann-Whitney U test, and Cronbach's alpha. RESULTS: Construct validity was satisfactory with the significant difference less than 0.001 between two groups (lowest through 25 percentile and higher than 75 percentile). The reliability coefficient for the Cronbach's alpha of the total scale of the KDQOL-36 were greater than 0.700 for all domains, range from 0.706 to 0.827. ICCs ranging from 0.713 to 0.999. CONCLUSIONS: The KDQOL-36 (Thai) is an appropriate tool for quality of life assessment and routine care in dialysis patients.
PUK28 WORK ABILITY AND LABOR SUPPLY AFTER KIDNEY TRANSPLANTATION
Neri L 1 , Dukes J 2 , Costa G 1 , Schnitztler M 2 1 University of Milan, Milan, Italy, 2 Saint Louis University, St. Louis, MO, USA OBJECTIVES: Initial mass dose, renal disease recurrence, and immunosuppressant nephrotoxicity affect long term graft function after kidney transplantation (KTx). Chronic Kidney Disease (CKD) may impair work ability, job performance and increase absenteeism. We sougt to evaluate the association of post-transplant CKD with work ability and labor supply. METHODS: We contacted all patients at 2 Midwestern KTx clinics. All consenting patients answered a questionnaire about sociodemographic characters, working conditions, quality of life and work ability (Work Ability Index, WAI). A second survey about labor supply was sent after 6 months. We abstracted biochemistry results, treatments and comorbidities data from clinical charts. We excluded patients with multiple or multi-organ transplant, and laboratory evidence of an acute cardiac ischemic episode in the month prior to assessment. At least one creatinine assessment in the 3 months screening period and age between 18-65 years was required for inclusion. We assessed differences in WAI and labor supply across CKD stages and Glomerular Filtration Rate (GFR) with ordinary least square regression. RESULTS: We enrolled 577 patients in 2 midwesten clinic (response rate 82%). Of them 222 met the inclusion/exclusion criteria. The employment-to-population ratio was 63%. Mean WAI score was 38.8Ϯ5.9. CKD severity was associated with WAI (ϭ -0.24, pϽ0.01). GFR was associated with WAI after adjusting for possible confounders (␤ϭ0.06; pϽ0.01). Ninty-three percent of patients responded to the follow up survey. Of those employed at baseline 20% lost their job and 25% of previously jobless had found one. Patients with severe CKD worked 4.69 weeks less than subject with mild or moderate CKD (pϭ0.03). GFR was associated with labor supply during the 6-months follow up after adjusting for possible confounders (␤ϭ0.07; pϭ0.03) CONCLUSIONS: Severe CKD was associated with a mild reduction in self-reported work ability and a strong reduction in labor supply after kidney transplant.
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ERYTHROPOIETIN-STIMULATING AGENT (ESA) DOSE RECOVERY FOLLOWING HOSPITALIZATION OF END STAGE RENAL DISEASE (ESRD) PATIENTS
Wang X 1 , Bond TC 1 , Rubin JL 1 , Yang A 2 1 DaVita Clinical Research, Minneapolis, MN, USA, 2 Affymax, Palo Alto, CA, USA OBJECTIVES: Hemodialysis (HD) patients are frequently hospitalized. Interruption of normal dialysis and 3x/weekly ESA treatments, along with the cause of hospitalization, usually leads to declines in Hb and increased ESA utilization post-hospitalization. To determine the impact of these changes on patient care and resource utilization, we assessed the time for HD patients to recover to prehospitalization ESA dose levels. METHODS: In this retrospective time-to-event analysis, we examined hospitalizations in adult (318 yrs old) HD patients from January 1, 2009 to December 31, 2010. Hospitalizations preceded by Ͼ 30 hospitalfree days were included. For patients experiencing increases in epoetin alfa (EPO) dose in the 30 days after hospitalization versus the 30 days before, we determined the number of days taken to achieve an EPO dose Յ the median per-session dose before hospitalization. Patient time was censored at re-hospitalization, transplant, death, or discontinuation of dialysis. Pre-hospitalization EPO dose level was considered achieved at the first of 3 consecutive dialysis sessions where EPO was given at a dose Յ the median per-session dose in the 30 days pre-hospitalization. RESULTS: A total of 88,627 hospitalization events were analyzed where EPO use increased post-hospitalization; in ϳ40% of these cases patients were censored (mainly due to re-hospitalization) before reaching pre-hospitalization dose. Of those where EPO dose recovered to pre-hospitalization levels, median time to recovery was 49 days (mean 102 days). Restricting the analysis to patients with pre-hospitalization median doses not in the top or bottom 10% of the range gave a median time to recovery of 51 days (mean 90 days). CONCLUSIONS: Hospitalizations frequently require an increase in post-hospitalization EPO dose. In 
